FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306.
Saved in:
| Title: | FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306. |
|---|---|
| Authors: | Holch JW; Department of Medicine III, University Hospital, LMU Munich, Germany; Comprehensive Cancer Center Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany. Electronic address: julian.holch@med.uni-muenchen.de., Ohnmacht AJ; Computational Health Center, Helmholtz Munich, Neuherberg, Germany; Department of Biology, LMU Munich, Germany., Stintzing S; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology (CCM), Berlin, Germany; German Cancer Consortium (DKTK), Partner Site Berlin and German Cancer Research Centre (DKFZ), Heidelberg, Germany., Heinrich K; Department of Medicine III, University Hospital, LMU Munich, Germany; Comprehensive Cancer Center Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany., Weiss L; Department of Medicine III, University Hospital, LMU Munich, Germany; Comprehensive Cancer Center Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany., Probst V; Department of Medicine III, University Hospital, LMU Munich, Germany; Comprehensive Cancer Center Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany., Stahler A; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology (CCM), Berlin, Germany; German Cancer Consortium (DKTK), Partner Site Berlin and German Cancer Research Centre (DKFZ), Heidelberg, Germany., Fischer von Weikersthal L; Gesundheitszentrum St Marien, Amberg, Germany., Decker T; Onkologie Ravensburg, Germany., Kiani A; Klinikum Bayreuth GmbH, Bayreuth, Germany and CCC Erlangen-EMN, Germany., Kaiser F; Praxis Hämatologie/Onkologie/Palliativmedizin-Tagesklinik, Landshut, Germany und VK&K Studien GbR, Landshut, Germany., Heintges T; Department of Medicine II, Städtische Kliniken Neuss, Germany., Kahl C; Städtisches Klinikum Magdeburg, Hämatologie/ Onkologie, Magdeburg, Germany; Department of Hematology, Oncology, and Palliative Care, University of Rostock, Rostock, Germany., Kullmann F; Klinikum Weiden, Medizinische Klinik I, Weiden, Germany., Link H; Department of Medicine I, Westpfalz-Klinikum GmbH, Kaiserslautern, Germany., Höffkes HG; Klinikum Fulda, Tumorklinik, Fulda, Germany., Moehler M; Medical Department 1, Johannes-Gutenberg Universität Mainz, Germany., Modest DP; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology (CCM), Berlin, Germany., Menden MP; Computational Health Center, Helmholtz Munich, Neuherberg, Germany; Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria, Australia., Heinemann V; Department of Medicine III, University Hospital, LMU Munich, Germany; Comprehensive Cancer Center Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany. |
| Source: | European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2025 May 02; Vol. 220, pp. 115388. Date of Electronic Publication: 2025 Mar 25. |
| Publication Type: | Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study |
| Journal Info: | Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9005373 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0852 (Electronic) Linking ISSN: 09598049 NLM ISO Abbreviation: Eur J Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40179821 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Holch+JW%22">Holch JW</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Germany; Comprehensive Cancer Center Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany. Electronic address: julian.holch@med.uni-muenchen.de.<br /><searchLink fieldCode="AU" term="%22Ohnmacht+AJ%22">Ohnmacht AJ</searchLink>; Computational Health Center, Helmholtz Munich, Neuherberg, Germany; Department of Biology, LMU Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Stintzing+S%22">Stintzing S</searchLink>; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology (CCM), Berlin, Germany; German Cancer Consortium (DKTK), Partner Site Berlin and German Cancer Research Centre (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Heinrich+K%22">Heinrich K</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Germany; Comprehensive Cancer Center Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Weiss+L%22">Weiss L</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Germany; Comprehensive Cancer Center Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Probst+V%22">Probst V</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Germany; Comprehensive Cancer Center Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Stahler+A%22">Stahler A</searchLink>; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology (CCM), Berlin, Germany; German Cancer Consortium (DKTK), Partner Site Berlin and German Cancer Research Centre (DKFZ), Heidelberg, Germany.<br /><searchLink fieldCode="AU" term="%22Fischer+von+Weikersthal+L%22">Fischer von Weikersthal L</searchLink>; Gesundheitszentrum St Marien, Amberg, Germany.<br /><searchLink fieldCode="AU" term="%22Decker+T%22">Decker T</searchLink>; Onkologie Ravensburg, Germany.<br /><searchLink fieldCode="AU" term="%22Kiani+A%22">Kiani A</searchLink>; Klinikum Bayreuth GmbH, Bayreuth, Germany and CCC Erlangen-EMN, Germany.<br /><searchLink fieldCode="AU" term="%22Kaiser+F%22">Kaiser F</searchLink>; Praxis Hämatologie/Onkologie/Palliativmedizin-Tagesklinik, Landshut, Germany und VK&K Studien GbR, Landshut, Germany.<br /><searchLink fieldCode="AU" term="%22Heintges+T%22">Heintges T</searchLink>; Department of Medicine II, Städtische Kliniken Neuss, Germany.<br /><searchLink fieldCode="AU" term="%22Kahl+C%22">Kahl C</searchLink>; Städtisches Klinikum Magdeburg, Hämatologie/ Onkologie, Magdeburg, Germany; Department of Hematology, Oncology, and Palliative Care, University of Rostock, Rostock, Germany.<br /><searchLink fieldCode="AU" term="%22Kullmann+F%22">Kullmann F</searchLink>; Klinikum Weiden, Medizinische Klinik I, Weiden, Germany.<br /><searchLink fieldCode="AU" term="%22Link+H%22">Link H</searchLink>; Department of Medicine I, Westpfalz-Klinikum GmbH, Kaiserslautern, Germany.<br /><searchLink fieldCode="AU" term="%22Höffkes+HG%22">Höffkes HG</searchLink>; Klinikum Fulda, Tumorklinik, Fulda, Germany.<br /><searchLink fieldCode="AU" term="%22Moehler+M%22">Moehler M</searchLink>; Medical Department 1, Johannes-Gutenberg Universität Mainz, Germany.<br /><searchLink fieldCode="AU" term="%22Modest+DP%22">Modest DP</searchLink>; Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology, and Cancer Immunology (CCM), Berlin, Germany.<br /><searchLink fieldCode="AU" term="%22Menden+MP%22">Menden MP</searchLink>; Computational Health Center, Helmholtz Munich, Neuherberg, Germany; Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Heinemann+V%22">Heinemann V</searchLink>; Department of Medicine III, University Hospital, LMU Munich, Germany; Comprehensive Cancer Center Munich, Germany; German Cancer Consortium (DKTK), Partner Site Munich and German Cancer Research Centre (DKFZ), Heidelberg, Germany. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229005373%22">European journal of cancer (Oxford, England : 1990)</searchLink> [Eur J Cancer] 2025 May 02; Vol. 220, pp. 115388. <i>Date of Electronic Publication: </i>2025 Mar 25. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Clinical Trial, Phase III; Randomized Controlled Trial; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science+Ltd%22">Elsevier Science Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9005373 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1879-0852 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209598049%22">09598049 </searchLink><i>NLM ISO Abbreviation: </i>Eur J Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40179821 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.ejca.2025.115388 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 115388 Titles: – TitleFull: FOLFIRI with cetuximab or bevacizumab in RAS wild-type metastatic colorectal cancer: Refining first-line treatment selection by combining clinical parameters: A post hoc analysis of the randomized open-label phase III trial FIRE-3/AIO KRK0306. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Holch JW – PersonEntity: Name: NameFull: Ohnmacht AJ – PersonEntity: Name: NameFull: Stintzing S – PersonEntity: Name: NameFull: Heinrich K – PersonEntity: Name: NameFull: Weiss L – PersonEntity: Name: NameFull: Probst V – PersonEntity: Name: NameFull: Stahler A – PersonEntity: Name: NameFull: Fischer von Weikersthal L – PersonEntity: Name: NameFull: Decker T – PersonEntity: Name: NameFull: Kiani A – PersonEntity: Name: NameFull: Kaiser F – PersonEntity: Name: NameFull: Heintges T – PersonEntity: Name: NameFull: Kahl C – PersonEntity: Name: NameFull: Kullmann F – PersonEntity: Name: NameFull: Link H – PersonEntity: Name: NameFull: Höffkes HG – PersonEntity: Name: NameFull: Moehler M – PersonEntity: Name: NameFull: Modest DP – PersonEntity: Name: NameFull: Menden MP – PersonEntity: Name: NameFull: Heinemann V IsPartOfRelationships: – BibEntity: Dates: – D: 02 M: 05 Text: 2025 May 02 Type: published Y: 2025 Identifiers: – Type: issn-electronic Value: 1879-0852 Numbering: – Type: volume Value: 220 Titles: – TitleFull: European journal of cancer (Oxford, England : 1990) Type: main |
| ResultId | 1 |
